Peptide payment processing for research-compound sellers

The distinction every underwriter is testing for

A risk analyst opening your website is answering one question in the first ninety seconds: is this a supplier of research materials, or is this an unapproved-drug business with a disclaimer? Everything else in the file — your volumes, your bank statements, your processing history — is read in the light of that answer.

The test is not what your products are. It is what your website says they are for. The patterns that fail it are consistent and easy to find:

• Quantity or frequency guidance anywhere on the site, including in a blog post or an FAQ
• Body-composition, recovery, performance or anti-ageing outcomes attached to a product
• Before-and-after imagery, or testimonials describing personal use
• Checkout copy, shipping options or packaging aimed at an individual buyer at home
• Affiliate or influencer content you do not control making claims you would never make

Businesses get declined for the fifth one more often than they expect. Acquirers run content checks against the whole indexed domain, not the pages you send them.

What the 2026 regulatory position actually is

The federal picture moved twice in 2026, and it matters because acquirers price uncertainty rather than reading the detail.

BPC-157 had been placed in Category 2 under section 503A of the Federal Food, Drug and Cosmetic Act — substances that raise significant safety concerns for compounding. In April 2026 the FDA removed it from that category. That removal did not put it on the 503A bulks list; it returned the substance to an evaluative state. In July 2026 the Pharmacy Compounding Advisory Committee recommended it for inclusion on the bulks list on an 8-6 vote. A final agency decision has not been published.

Two things follow for a payments application:

1. Compounding status is not supply status. Whether a 503A pharmacy may compound a substance is a different legal question from whether a supplier may sell it for laboratory use. Underwriters routinely conflate them, so be ready to explain the distinction in plain language rather than assuming it is understood.
2. A close committee vote reads as instability. An 8-6 recommendation pending a final decision is, to a risk team, a category that could change again. That is priced into your rate and your reserve, and it is why reserves in this vertical sit at the higher end.

Meanwhile enforcement volume is rising. FDA warning letters touching research peptides ran at roughly fourteen across 2024; comparable quarterly counts in 2026 are several times that rate. Risk teams monitor the same publication feed. A letter naming a business in your category tightens appetite for everyone in it for weeks afterwards.

Why there are no state pages here

Most high-risk categories reward a state-by-state breakdown. Kratom is banned outright in around ten states and regulated under a Consumer Protection Act framework in eighteen or more. Vape faces state flavour bans on top of the federal PACT Act. Those distinctions change which merchants can be boarded where, so a state page earns its place.

Peptides are not like that. This category is regulated federally through the FDA, and as of August 2026 no state has enacted a peptide-specific prohibition. Pages claiming otherwise — state registration schemes, chain-of-custody reporting windows, state-specific safety-sheet rules — trace back to vendor marketing content rather than to any statute or agency rule we could locate.

We would rather publish nothing than publish a regulatory claim we cannot source. If your counsel has identified a genuine state-level requirement that affects boarding, tell us and we will cover it properly, with the citation attached.

The scheme registration cost nobody quotes you upfront

When an acquirer boards a merchant in this category, both card schemes require the merchant to be registered as high-risk, and both charge for it. Visa’s Integrity Risk Programme applies an annual registration fee per acquiring relationship together with a per-transaction component and a charge on processed volume. Mastercard’s Specialty Merchant Registration Program works similarly, and its fees were revised upward during 2026 — including a substantial new annual licence fee levied on the acquirer, not the merchant.

That last point explains something merchants find baffling. An acquirer carrying a large fixed cost for the privilege of registering specialty merchants needs enough volume from the category to justify it. This is why a well-run business at fifteen thousand dollars a month can be harder to place than a messier one at three hundred thousand, and why “we are not taking new merchants in that vertical this quarter” is a real answer rather than a brush-off.

It is also why we ask for your volume band before anything else. It is the fastest way to tell you honestly whether the economics work.

A realistic sequence

1. Fix the site before you apply. Every application you submit and lose leaves a footprint. Get the positioning right once, then apply.
2. Assemble the file. Certificates of analysis, supplier invoices, bank and processing statements, ownership documents. Complete files are placed in days; incomplete ones sit for weeks.
3. Pre-qualify. Five questions tells us whether the category, your volume and your jurisdiction line up with what any provider is boarding right now.
4. One introduction at a time. We introduce you to the provider whose appetite fits, and you deal with them directly from there. We do not broadcast your application to every partner at once — that is not what the consent you give us covers, and a provider who knows they are in a race reads your file differently from one who knows they fit.